Trial Profile

Phase I study of HM 12525A in patients with type 2 diabetes mellitus

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efinopegdutide (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Therapeutic Use

Most Recent Events

28 May 2014 New trial record
16 May 2014 This trial received approval in Germany in April 2014, according to a Hanmi Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com